As shown in this study, IgY antibodies may also be used in this context and further studies are necessary to determine whether these specific antibodies could be employed in therapeutical protocols during acute toxoplasmosis, especially in immunizations performed with single antigens. In conclusion, our results demonstrated that polyclonal IgY anti-STAg antibodies are a promising complementary tool for studies of the T. gondii infection model.